Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

The effects of thrombomodulin and activated protein C on the pathogenesis of multiple sclerosis.
Mapping Variation in Cellular and Transcriptional Response to 1,25-Dihydroxyvitamin D3 in Peripheral Blood Mononuclear Cells.
Myeloid cells - targets of medication in multiple sclerosis.
Resveratrol Defends Blood-brain Barrier Integrity in Experimental Autoimmune Encephalomyelitis Mice.
Importance of latency and amplitude values of recurrent laryngeal nerve during thyroidectomy in diabetic patients.
Future placebo-controlled trials of disease modifying therapy in relapsing multiple sclerosis would be unethical: No.
The role of the wnt canonical signaling in neurodegenerative diseases.
If they are OK, we are OK: the experience of partners living with neuromyelitis optica.
Oculomotor Nerve Palsy as a Rare Presentation and First Sign of Multiple Myeloma.
Atypical inflammatory demyelinating syndromes of the CNS.
Thrombin and protein C pathway in peripheral nerve Schwann cells.
Human leucocyte antigen (HLA) class I and II typing in Belgian multiple sclerosis patients.
Effect of thyreotrope-releasing hormone (TRH) on prolactin turnover in culture.
Association of Pentraxin 3 with Autoimmune Diseases: A Systematic Review and Meta-Analysis.
Current status of biomarker research in neurology.
Multiple sclerosis: Rapid diagnosis or right diagnosis?
Assessing Functional Decline in Neurological Diseases Clinical Trials: Duration of Follow-Up - The Case of Multiple Sclerosis.
[Experience of application of Russian biosimilar of interferon beta-1b for treatment of pediatric multiple sclerosis].
Data quality evaluation for observational multiple sclerosis registries.
Expression of switch-associated protein 70 is associated with lymphocyte activation and reduced disability in multiple sclerosis.
Angiotensin-converting enzyme insertion/deletion gene polymorphism in multiple sclerosis: a meta-analysis.
Preclinical Metabolism, Pharmacokinetics and In Vivo Analysis of New Blood-Brain-Barrier Penetrant Fingolimod Analogues: FTY720-C2 and FTY720-Mitoxy.
Comparative effectiveness using a matching-adjusted indirect comparison between delayed-release dimethyl fumarate and fingolimod for the treatment of multiple sclerosis.
Walking fatigability in multiple sclerosis: A comparison between the 2- and the 6-minute walk test and an evaluation of associated factors.
The experience of transitioning from relapsing remitting to secondary progressive multiple sclerosis: views of patients and health professionals.

Pages